ResearcherJohns Hopkins UniversityActive in the last 2 years

Kai-li Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2352-6318. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 2 papers

Papers 2

Emerging Systemic Therapy Considerations for Pancreatic Cancer. Co-author DOI 10.1016/j.semradonc.2025.07.006 ↗
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting. Co-author DOI 10.3390/cancers17071246 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nilofer Saba Azad · 1 shared paper, 2025 · strength 0.54
- Paper Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting. DOI 10.3390/cancers17071246 ↗
Matthew Z. Guo · 1 shared paper, 2025 · strength 0.42
- Paper Emerging Systemic Therapy Considerations for Pancreatic Cancer. DOI 10.1016/j.semradonc.2025.07.006 ↗
Neeha Zaidi · 1 shared paper, 2025 · strength 0.42
- Paper Emerging Systemic Therapy Considerations for Pancreatic Cancer. DOI 10.1016/j.semradonc.2025.07.006 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.